Duration of clopidogrel-based dual antiplatelet therapy and clinical outcomes after endeavor sprint zotarolimus-eluting stent implantation in patients presenting with acute coronary syndrome


      • We performed analysis of ACS patients receiving DAPT using clopidogrel >6 months vs. ≤6 months.
      • MACCE did not differ between those 2 groups.
      • In our clinical setting of ACS, the optimal duration of DAPT after DES implantation was not longer than 6 months.



      The optimal duration of dual antiplatelet therapy (DAPT) remains controversial in patients with acute coronary syndrome (ACS). We sought to compare outcomes after the implantation of zotarolimus-eluting stent (ZES) between patients with ACS who received clopidogrel-based DAPT for >6 months and those treated for ≤6 months.


      From a registry of patients treated with ZESs between October 2005 and January 2010, 1740 patients with ACS were selected for the present analysis. Landmark analyses were performed for ACS patients who were event-free at 6 months follow-up (n = 1674). The primary outcome was a major adverse cardiac and cerebrovascular event (MACCE), including all-cause death, myocardial infarction (MI), target vessel revascularization (TVR), stent thrombosis, or stroke. We also performed adjustments for the baseline characteristics of patients, using their propensity-score matching (n = 469 pairs).


      During a median follow-up of 22.5 months, the rate of MACCE was 6.4% in patients with DAPT >6 months (n = 1140) and 4.7% in patients with DAPT ≤6 months (n = 534) (adjusted hazard ratio [HR] 1.05; 95% confidence interval [CI] 0.61–1.82; p = 0.86). After propensity-score matching, DAPT >6 months was not found to be associated with a lower incidence of MACCE compared with DAPT ≤6 months (adjusted HR 0.80, 95% CI 0.44–1.45, p = 0.46). The rates of all-cause death or MI, TVR, stent thrombosis, and stroke also did not differ significantly between two groups.


      DAPT for >6 months do not seem to be associated with improved clinical outcomes in patients with ACS undergoing percutaneous coronary intervention (PCI) with ZES.


      ACS (acute coronary syndrome), CI (confidence interval), DESs (drug-eluting stents), DAPT (dual antiplatelet therapy), HR (hazard ratio), MACCE (major adverse cardiac and cerebrovascular event), MI (myocardial infarction), PCI (percutaneous coronary intervention), TVR (target vessel revascularization), ZES (zotarolimus-eluting stents)


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Windecker S.
        • Kolh P.
        • Alfonso F.
        • Collet J.P.
        • Cremer J.
        • Falk V.
        • et al.
        2014 ESC/EACTS guidelines on myocardial revascularization.
        Eur Heart J. 2014; 35: 2541-2619
        • Feres F.
        • Costa R.A.
        • Abizaid A.
        • Leon M.B.
        • Marin-Neto J.A.
        • Botelho R.V.
        • et al.
        Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
        JAMA. 2013; 310: 2510-2522
        • Gwon H.C.
        • Hahn J.Y.
        • Park K.W.
        • Song Y.B.
        • Chae I.H.
        • Lim D.S.
        • et al.
        Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
        Circulation. 2012; 125: 505-513
        • Kim B.K.
        • Hong M.K.
        • Shin D.H.
        • Nam C.M.
        • Kim J.S.
        • Ko Y.G.
        • et al.
        A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation).
        J Am Coll Cardiol. 2012; 60: 1340-1348
        • Thygesen K.
        • Alpert J.S.
        • Jaffe A.S.
        • Simoons M.L.
        • Chaitman B.R.
        • White H.D.
        • et al.
        Third universal definition of myocardial infarction.
        Circulation. 2012; 126: 2020-2035
        • Cutlip D.E.
        • Windecker S.
        • Mehran R.
        • Boam A.
        • Cohen D.J.
        • van Es G.A.
        • et al.
        Clinical end points in coronary stent trials: a case for standardized definitions.
        Circulation. 2007; 115: 2344-2351
        • Yusuf S.
        • Zhao F.
        • Mehta S.R.
        • Chrolavicius S.
        • Tognoni G.
        • Fox K.K.
        • et al.
        Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
        N Engl J Med. 2001; 345: 494-502
        • Eisenstein E.L.
        • Anstrom K.J.
        • Kong D.F.
        • Shaw L.K.
        • Tuttle R.H.
        • Mark D.B.
        • et al.
        Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation.
        JAMA. 2007; 297: 159-168
        • Daida H.
        • Miyauchi K.
        • Ogawa H.
        • Yokoi H.
        • Matsumoto M.
        • Kitakaze M.
        • et al.
        Management and two-year long-term clinical outcome of acute coronary syndrome in Japan: prevention of atherothrombotic incidents following ischemic coronary attack (PACIFIC) registry.
        Circ J. 2013; 77: 934-943
        • Fajadet J.
        • Wijns W.
        • Laarman G.J.
        • Kuck K.H.
        • Ormiston J.
        • Baldus S.
        • et al.
        Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II study.
        EuroIntervention. 2010; 6: 562-567
        • Mauri L.
        • Massaro J.M.
        • Jiang S.
        • Meredith I.
        • Wijns W.
        • Fajadet J.
        • et al.
        Long-term clinical outcomes with zotarolimus-eluting versus bare-metal coronary stents.
        JACC Cardiovasc Interv. 2010; 3: 1240-1249
        • Hahn J.Y.
        • Song Y.B.
        • Choi J.H.
        • Choi S.H.
        • Lee S.Y.
        • Park H.S.
        • et al.
        Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents: the DATE (Duration of Dual Antiplatelet Therapy AfterImplantation of Endeavor Stent) registry.
        Circ J. 2010; 74: 2314-2321
        • Kim J.S.
        • Jang I.K.
        • Fan C.
        • Kim T.H.
        • Kim J.S.
        • Park S.M.
        • et al.
        Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the ENDEAVOR OCT trial.
        JACC Cardiovasc Interv. 2009; 2: 1240-1247
        • Kim J.W.
        • Seo H.S.
        • Park J.H.
        • Na J.O.
        • Choi C.U.
        • Lim H.E.
        • et al.
        A prospective, randomized, 6-month comparison of the coronary vasomotor response associated with a zotarolimus- versus a sirolimus-eluting stent: differential recovery of coronary endothelial dysfunction.
        J Am Coll Cardiol. 2009; 53: 1653-1659
        • Varenhorst C.
        • Jensevik K.
        • Jernberg T.
        • Sundstrom A.
        • Hasvold P.
        • Held C.
        • et al.
        Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome.
        Eur Heart J. 2014; 35: 969-978
        • Mauri L.
        • Kereiakes D.J.
        • Yeh R.W.
        • Driscoll-Shempp P.
        • Cutlip D.E.
        • Steg P.G.
        • et al.
        Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
        N Engl J Med. 2014; 371: 2155-2166
        • Costa F.
        • Vranckx P.
        • Leonardi S.
        • Moscarella E.
        • Ando G.
        • Calabro P.
        • et al.
        Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial.
        Eur Heart J. Feb 25 2015; 36: 1242-1251
        • Gilard M.
        • Barragan P.
        • Noryani A.A.
        • Noor H.A.
        • Majwal T.
        • Hovasse T.
        • et al.
        6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial.
        J Am Coll Cardiol. Nov 16 2014; (pii: S0735-1097(14)06970-8.[Epub ahead of print])
        • Ndrepepa G.
        • Schulz S.
        • Neumann F.J.
        • Laugwitz K.L.
        • Richardt G.
        • Byrne R.A.
        • et al.
        Prognostic value of bleeding after percutaneous coronary intervention in patients with diabetes.
        EuroIntervention. 2014; 10: 83-89
        • Steg P.G.
        • Huber K.
        • Andreotti F.
        • Arnesen H.
        • Atar D.
        • Badimon L.
        • et al.
        Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology.
        Eur Heart J. 2011; 32: 1854-1864
        • Bonhomme F.
        • Fontana P.
        • Reny J.L.
        How to manage prasugrel and ticagrelor in daily practice.
        Eur J Intern Med. 2014; 25: 213-220
        • Valgimigli M.
        • Borghesi M.
        • Tebaldi M.
        • Vranckx P.
        • Parrinello G.
        • Ferrari R.
        Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY).
        Eur Heart J. 2013; 34: 909-919
        • Ranucci M.
        • Castelvecchio S.
        • Menicanti L.
        • Frigiola A.
        • Pelissero G.
        Risk of assessing mortality risk in elective cardiac operations: age, creatinine, ejection fraction, and the law of parsimony.
        Circulation. 2009; 119: 3053-3061